

Avalanche Biotechnologies

Pharma & biotech

21 May 2015

Solving ophthalmic gene therapy

Avalanche is well capitalised to deliver all important proof-of-concept data in 2015 with trial readout in wet AMD. By combining its gene therapy technology platform with vascular endothelial growth factor (VEGF) trap molecules, Avalanche is aiming to break into the \$6bn exudative AMD market. With \$290m in cash and a Regeneron licensing deal for orphan diseases, Avalanche is well placed to deliver on its clinical programmes.

AVA-101 clinical trials progressing

Avalanche has completed enrolment in a Phase IIa trial of its lead product, AVA-101 and is expecting data mid-year. The Phase I trial enrolled eight patients with wet AMD randomised to low dose, high dose and control. All patients in the phase I study received two initial Lucentis doses followed by rescue Lucentis if needed. Control eyes lost five letters of visual acuity in the first year. The low-dose AVA-101 group gained 8.7 letters and the high-dose group gained 6.3 letters. The AVA-101 groups needed an average of 0.33 rescue injections, compared to 3.0 for the control groups. One patient lost vision due to subretinal scarring at baseline.

Phase IIa data coming soon

Phase IIa enrolled 32 patients and top-line data are expected this summer. Interim data presented by the company in mid-2014 suggested the injection continues to be well tolerated. Pending these results, the company plans to submit an IND application to begin a Phase IIb in the US. AVA-201 for the prevention of exudative AMD is in planning stage and AVA-322/323 for colour blindness is preclinical targeting a 2016 IND filing. The next generation platform technology has a wide range of targets.

AVA-101 offers an advantage over current therapy

Competition exists for treatment of exudative AMD. There are two approved anti-VEGF injections, Lucentis and Eylea, each requiring repeated injections. AVA-101's phase I data showed that it may decrease the number of injections needed.

Valuation: EV of \$707m with strong capital position

A market cap of \$997m and \$290m in cash places Avalanche in a good position. There is upside potential this year with expected Phase IIa data and US IND submission. The Regeneron licensing agreement to develop the x-linked retinoschisis product and to identify new targets will provide near-term revenue.

Consensus estimates

Year end	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/13	0.5	(5.3)	(1.44)	0.0	N/A	N/A
12/14	0.6	(25.4)	(2.46)	0.0	N/A	N/A
12/15e	3.7	(46.4)	(1.95)	0.0	N/A	N/A
12/16e	4.3	(63.1)	(2.50)	0.0	N/A	N/A

Source: Bloomberg

Price **\$39.05**
Market cap **\$997m**

Share price graph



Share details

Code AAVL
Listing NASDAQ
Shares in issue 25.53m

Business description

Avalanche is a clinical-stage biotechnology company focused on adeno-associated virus-based gene therapy for age-related macular degeneration. The company's Ocular BioFactory platform is capable of encoding genes to express therapeutic proteins at high yields. The company is in Phase II trials in AMD.

Bull

- Encouraging Phase I completed and Phase IIa data expected soon.
- Scalable platform with wide range of targets.
- Strong capital position with \$290m in cash.

Bear

- Competition in the exudative AMD market.
- Only one compound is currently in clinical stage.
- Current trials conducted in Australia and FDA may require additional data, delaying IND filing.

Analysts

George Magrath, MD MBA +44 (0)20 3077 5700
Christian Glennie +44 (0)20 3077 57 27

healthcare@edisongroup.com

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2015]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.